Conversations in cardiology: bridging antiplatelet therapy before surgery

Catheter Cardiovasc Interv. 2014 Apr 1;83(5):748-52. doi: 10.1002/ccd.25319. Epub 2014 Jan 6.

Abstract

Bridging for antiplatelet therapy remains a subject of debate with data favoring GP blockers but at a risk of bleeding. This Conversation in Cardiology addresses a key and often asked question about use of alternatives to P2Y12 agents in patients requiring surgery within 6 months after drug eluting stent implantation.

Keywords: antiplatelet therapy; stent thrombosis.

MeSH terms

  • Coronary Thrombosis / economics
  • Coronary Thrombosis / etiology
  • Coronary Thrombosis / prevention & control*
  • Cost-Benefit Analysis
  • Drug Administration Schedule
  • Drug Costs
  • Hemorrhage / chemically induced
  • Humans
  • Percutaneous Coronary Intervention* / adverse effects
  • Perioperative Care
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / economics
  • Purinergic P2Y Receptor Antagonists / administration & dosage*
  • Purinergic P2Y Receptor Antagonists / adverse effects
  • Purinergic P2Y Receptor Antagonists / economics
  • Surgical Procedures, Operative* / economics
  • Time Factors
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists